(SeaPRwire) –   ESCHBORN, Germany, May 11, 2026 — Sino Biological Europe GmbH, the European branch of the international life science reagent and service provider Sino Biological, has introduced the EliteScience VIP Partnership program. This premium service is designed to assist top-tier universities, research centers, pharmaceutical firms, and biotech companies throughout Europe.

The EliteScience initiative provides a variety of exclusive perks without any annual membership costs, with the goal of eliminating research obstacles and speeding up scientific breakthroughs for European scientists. The program features three primary benefits: guaranteed priority for production and delivery to reduce wait times, a risk-free CRO service model based on a “no results, no fees” policy, and early access to complimentary reagent samples from a catalog of over 77,000 items.

Participants receive extensive support, including dedicated one-on-one technical assistance, 24-hour responses from local specialists, and benefits such as price stability and volume discounts. Furthermore, the program offers a wide array of academic initiatives and comprehensive research tools, helping scientists improve their research productivity and increase the impact of their publications.

As a localized program for the European scientific community, EliteScience is tailored to meet regional procurement standards and research requirements, effectively connecting high-quality life science products with local needs. “EliteScience demonstrates our dedication to providing European researchers with top-tier resources and responsive service,” stated Dr. Bin Hu, Head of Sino Biological Europe GmbH. “This launch highlights our commitment to building lasting partnerships. By offering priority access, predictable costs, and personalized support, we enable our partners to translate their concepts into results more efficiently.”

About Sino Biological

Established in 2007, Sino Biological is an international biotechnology firm that focuses on high-quality antibodies, recombinant proteins, and CRO services. The company assists researchers in more than 90 countries, supporting vaccine development, drug discovery, basic research, and diagnostics through its broad product range, proprietary quality control systems, and advanced research platforms.

Forward-Looking Statements

Certain portions of this document contain “forward-looking statements” as defined by the Private Securities Litigation Reform Act. These statements reflect the current expectations of Sino Biological’s management and are subject to risks and changing circumstances. Actual outcomes may vary significantly from those projected due to various factors beyond the company’s control. Sino Biological does not intend to, and assumes no responsibility to, update these forward-looking statements.

For media inquiries or partnership opportunities, please contact:

Sino Biological, Inc.
gmo@sinobiological.cn
www.sinobiological.com